GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Cyclically Adjusted Price-to-FCF

Fortress Biotech (FRA:CNB1) Cyclically Adjusted Price-to-FCF : (As of May. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Fortress Biotech's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Cyclically Adjusted Price-to-FCF Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fortress Biotech's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted Price-to-FCF falls into.



Fortress Biotech Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Fortress Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Fortress Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.613/131.7762*131.7762
=-2.613

Current CPI (Mar. 2024) = 131.7762.

Fortress Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.231 100.560 -1.613
201409 -0.878 100.428 -1.152
201412 -1.148 99.070 -1.527
201503 -3.622 99.621 -4.791
201506 -2.705 100.684 -3.540
201509 -2.233 100.392 -2.931
201512 -2.713 99.792 -3.583
201603 -4.811 100.470 -6.310
201606 -3.884 101.688 -5.033
201609 -3.757 101.861 -4.860
201612 -6.818 101.863 -8.820
201703 -4.309 102.862 -5.520
201706 -7.928 103.349 -10.109
201709 -8.013 104.136 -10.140
201712 -6.453 104.011 -8.176
201803 -8.205 105.290 -10.269
201806 -8.267 106.317 -10.247
201809 -8.000 106.507 -9.898
201812 -7.248 105.998 -9.011
201903 -5.331 107.251 -6.550
201906 -7.159 108.070 -8.729
201909 -4.795 108.329 -5.833
201912 -6.729 108.420 -8.179
202003 -5.060 108.902 -6.123
202006 -3.590 108.767 -4.349
202009 -4.460 109.815 -5.352
202012 -3.407 109.897 -4.085
202103 -3.451 111.754 -4.069
202106 -6.043 114.631 -6.947
202109 -4.583 115.734 -5.218
202112 -6.700 117.630 -7.506
202203 -7.611 121.301 -8.268
202206 -9.871 125.017 -10.405
202209 -7.507 125.227 -7.900
202212 -4.406 125.222 -4.637
202303 -5.943 127.348 -6.150
202306 -4.165 128.729 -4.264
202309 -2.098 129.860 -2.129
202312 -3.584 129.419 -3.649
202403 -2.613 131.776 -2.613

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fortress Biotech  (FRA:CNB1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Fortress Biotech Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Industry
Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines